Table 1. Characteristics of 8365 patients who underwent radical prostatectomy and bilateral pelvic lymph node dissection for localised prostate cancer.
|
Development cohort (n=4770) |
Validation cohort (n=3595) |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Patients |
Lymph nodes examined |
Patients |
Lymph nodes examined |
|||||||||
| No. | % | Mean | s.d. | Median | IQR | No. | % | Mean | s.d. | Median | IQR | |
|
Clinical T stage | ||||||||||||
| cT1 | 3298 | 69.1 | 6.9 | 6.0 | 5.0 | 6 | 1883 | 52.4 | 17.2 | 8.1 | 16.0 | 11 |
| cT2 | 1367 | 28.7 | 8.2 | 6.5 | 6.0 | 8 | 1231 | 34.2 | 17.5 | 8.4 | 16.0 | 11 |
| cT3 |
105 |
2.2 |
9.2 |
6.2 |
7.0 |
7 |
481 |
13.4 |
19.5 |
10.0 |
18.0 |
12 |
|
Bx Gleason score | ||||||||||||
| 6 | 2121 | 44.5 | 5.94 | 5.0 | 5.0 | 5 | 2230 | 62.0 | 17.1 | 7.9 | 16.0 | 11 |
| 7 | 2063 | 43.2 | 8.0 | 6.6 | 6.0 | 8 | 1020 | 28.4 | 17.9 | 8.6 | 17.0 | 11 |
| 8–10 |
586 |
12.3 |
9.7 |
7.6 |
9.0 |
8 |
345 |
9.6 |
20.1 |
11.1 |
18.0 |
13 |
|
Pathological T stage | ||||||||||||
| pT2 | 3234 | 67.6 | 6.8 | 5.7 | 5.0 | 6 | 2381 | 66.2 | 17.9 | 8.0 | 16.0 | 11 |
| pT3a | 1103 | 23.1 | 8.2 | 6.6 | 6.0 | 7 | 587 | 16.3 | 18.2 | 8.6 | 17.0 | 11 |
| pT3b/T4 |
443 |
9.3 |
9.7 |
7.4 |
8.0 |
9 |
627 |
17.4 |
19.1 |
9.9 |
17.0 |
10 |
|
RP Gleason score | ||||||||||||
| 6 | 1135 | 23.8 | 5.6 | 4.4 | 5.0 | 4 | 1387 | 38.6 | 17.0 | 7.9 | 16.0 | 11 |
| 7 | 3170 | 66.4 | 7.7 | 6.4 | 6.0 | 7 | 1685 | 46.9 | 17.4 | 8.3 | 16.0 | 11 |
| 8–10 |
467 |
9.8 |
9.1 |
7.3 |
7.0 |
9 |
523 |
14.5 |
20.0 |
10.1 |
18.0 |
11 |
|
Surgical margin | ||||||||||||
| Negative | 4029 | 84.5 | 7.2 | 6.1 | 5.0 | 6 | 2588 | 72.0 | 17.2 | 8.1 | 16.0 | 11 |
| Positive |
741 |
15.5 |
8.3 |
6.5 |
6.0 |
8 |
1007 |
28.0 |
18.7 |
9.3 |
17.0 |
11 |
|
Pathological N stage | ||||||||||||
| N0 | 4514 | 94.6 | 7.2 | 6.0 | 6.0 | 6 | 3131 | 87.1 | 17.1 | 7.9 | 16.0 | 11 |
| N+ |
256 |
5.4 |
10.4 |
8.1 |
10.0 |
6 |
464 |
12.9 |
21.3 |
11.0 |
19.0 |
11 |
|
Preoperative PSA (ng ml−1) | ||||||||||||
| <10 | 3830 | 80.3 | 7.1 | 6.0 | 5.0 | 6 | 2492 | 69.3 | 17.4 | 8.3 | 16.0 | 11 |
| ⩾10 | 940 | 19.7 | 8.6 | 6.7 | 6.0 | 7 | 1103 | 30.7 | 18.1 | 9.0 | 17.0 | 10 |
|
Development cohort (n=4770) |
Validation cohort (n=3595) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Median | Mean | Range | IQR | Median | Mean | Range | IQR | |
| Age (years) |
62.0 |
61.3 |
45–82 |
10 |
66.0 |
65.5 |
40–89 |
10 |
| No. of examined LNs in all patients |
6.0 |
7.4 |
1–55 |
7 |
16.0 |
17.6 |
5–73 |
11 |
| No. of examined LNs in patients with negetive LNs |
6.0 |
7.2 |
1–55 |
6 |
16.0 |
17.8 |
5–66 |
11 |
| No. of examined LNs in patients with positive LNs |
10.0 |
10.4 |
1–38 |
10 |
19.0 |
21.3 |
5–73 |
11 |
| No. of positive LNs in patients with positive LNs | 1.0 | 1.8 | 1–23 | 1 | 2.0 | 3.81 | 1.6 | 2 |
Abbreviations: IQR=interquartile range; LNs=lymph nodes; PSA=prostate-specific antigen; RP=radical prostatectomy; s.d.=standard deviation.